UroGen Pharma reports long-term follow-up study with JELMYTO

UroGen Pharma (URGN) highlights a duration of response of nearly four years from a long-term follow-up study with JELMYTO for pyelocalyceal solution, which is FDA-approved for the treatment of low-grade upper tract urothelial cancer, LG-UTUC, in adult patients. Among patients from the OLYMPUS trial who achieved a complete response after primary chemoablation with JELMYTO, the median duration of response was 47.8 months, irrespective of whether their cancer was new-onset or recurrent. Of these patients, 21 had new-onset UTUC, and 20 had recurrent UTUC at baseline; there were no significant differences in durability between groups, with 8 patients in each group experiencing recurrence or death not due to treatment. Twenty patients entered long-term follow-up with a median follow-up of 53.3 months; median duration of response was not estimable due to the low event rate.